Summary

The global Alcohol and Drug Abuse Testing Service market is projected to grow from US$ 5760 million in 2025 to US$ 8446 million by 2032, at a CAGR of 5.6% (2026-2032), driven by critical product segments and diverse end‑use applications.
Alcohol and Drug Abuse Testing Service refers to professional third-party testing services used to identify alcohol, illicit drugs, controlled substances, prescription medications and related metabolites or biomarkers in human specimens. The service is delivered through toxicology laboratories, occupational health providers, testing program administrators, forensic laboratories and integrated screening platforms, with common specimen matrices including urine, oral fluid, hair, nails, blood and breath. Typical workflows cover donor identification, specimen collection, chain-of-custody management, initial immunoassay or rapid screening, specimen-validity testing, confirmatory or definitive analysis using technologies such as GC-MS and LC-MS/MS, Medical Review Officer review, digital reporting and compliance administration. The market primarily serves workplace and employment screening, safety-sensitive industries, clinical medication and substance-use monitoring, courts and correctional programs, social services and personal testing. The study focuses on commercially delivered testing and associated professional services across the testing workflow, with revenue attributed according to the actual value delivered by laboratories, collection networks, program administrators and related professional service providers.
Key Findings
North America accounted for approximately 68%–70% of 2025 revenue under the report’s narrow commercial-services scope
Workplace and employment testing represented about 54.7% of 2025 revenue and remained the largest application segment
Clinical medication and substance-use monitoring contributed about 23.4% of 2025 revenue and carried higher testing value per case
The market combines large laboratory and screening platforms with a broad regional long tail of specialist toxicology and occupational testing providers
Market Trends
Alcohol and Drug Abuse Testing Service is evolving from standardized urine-based workplace screening toward a multi-specimen, digitally managed and more analytically sophisticated service model. Urine remains the most established matrix because of its mature laboratory infrastructure and favorable economics, while oral fluid is gaining strategic importance where directly observed collection and shorter detection windows are desirable. Hair and nail testing are increasingly used when customers require evidence covering a longer retrospective period, and definitive LC-MS/MS analysis is becoming more important for complex drug panels, synthetic opioids, fentanyl-related compounds and clinical medication monitoring. At the same time, electronic chain-of-custody, online scheduling, automated result delivery and integration with employer screening systems are shifting competitive differentiation from individual laboratory tests toward end-to-end workflow management. In U.S. federally regulated transportation testing, oral-fluid implementation continues to depend on the availability of qualified HHS-certified laboratory infrastructure, illustrating how regulatory readiness can influence the adoption pace of new testing routes.
Market Dynamics
Drivers
Demand is supported by the continuing requirement of employers and safety-sensitive industries to manage workplace safety, regulatory compliance and post-incident risk, together with growing demand from behavioral health, substance-use treatment and clinical medication monitoring. Transportation, construction, mining, energy and other high-risk operating environments provide recurring testing demand, while courts, corrections and social-service programs add another relatively stable demand base. The U.S. Department of Transportation continues to maintain detailed procedures governing workplace drug and alcohol testing for federally regulated transportation employees, supporting a durable compliance-driven testing ecosystem.
Restraints
The market is constrained by substantial differences in labor law, privacy rules, cannabis policy and employer testing rights across jurisdictions. Random or pre-employment testing that is established practice in one country may face significant legal or cultural restrictions in another, limiting the ability of global providers to standardize testing programs. Conventional urine testing also faces pricing pressure because of mature laboratory capacity and intense competition, while advanced matrices and definitive testing require more specialized analytical capabilities, trained personnel and quality-control systems. Changes in drug legalization and employment policy can additionally alter which substances employers are permitted or willing to include in screening panels.
Opportunities
The most attractive opportunities are shifting toward higher-value testing applications rather than simple expansion of conventional screening volumes. Oral-fluid collection, hair and nail testing, expanded synthetic-drug panels, fentanyl-related testing and definitive mass-spectrometry analysis allow providers to address different detection windows and more complex customer requirements. Digital ordering, electronic chain-of-custody, API connectivity and integrated occupational-health workflows create additional opportunities for laboratories and testing administrators to deepen customer relationships. Markets where commercial toxicology outsourcing remains fragmented, particularly parts of Asia Pacific and emerging economies, also provide room for specialized providers and laboratory networks to expand professional third-party testing capabilities.
Challenges
Long-term challenges include maintaining analytical accuracy as drug profiles evolve, controlling false-positive and false-negative risk, protecting sensitive personal information and providing legally defensible chain-of-custody documentation. Providers operating across multiple countries must adapt to materially different regulatory frameworks while maintaining consistent service quality. The industry also faces structural complexity because a single testing event may involve a collection site, laboratory, Medical Review Officer and third-party administrator, creating pressure on service coordination and price transparency. New specimen matrices can expand the addressable service portfolio, but regulated adoption may lag technical availability when laboratory certification, operating standards or employer policies are not yet fully aligned.
Value Chain Analysis
The value chain of Alcohol and Drug Abuse Testing Service begins with analytical instruments, diagnostic reagents, specimen-collection devices, breath-testing equipment, logistics systems and digital compliance infrastructure. These upstream inputs support the midstream service network formed by toxicology and clinical laboratories, occupational-health clinics, mobile collectors, Medical Review Officers, third-party administrators and digital screening platforms. Value is progressively created through reliable specimen collection, documented chain of custody, analytical screening, confirmatory testing, professional review, regulatory compliance and actionable result delivery. U.S. federal testing rules formally recognize multiple service-agent roles, demonstrating that testing is an integrated professional workflow rather than a single laboratory transaction.
Commercial value varies materially by service model. High-volume standardized workplace urine screening depends heavily on laboratory utilization, collection-network efficiency and logistics, whereas hair, nail and definitive toxicology services generally generate greater value per testing event because of more specialized analytical requirements. TPA and screening-platform providers create value through customer acquisition, program administration, scheduling, compliance and data integration, while laboratories capture analytical value. Because multiple providers may participate in the same testing event, market revenue analysis requires careful allocation of laboratory, collection and administration revenue to avoid double counting pass-through testing charges.
Segment Insights
By testing purpose, workplace and employment testing is the largest segment, accounting for approximately 54.7% of 2025 market revenue under the report’s narrow scope. Its scale reflects recurring requirements across pre-employment, random, post-incident, reasonable-suspicion, return-to-duty and follow-up programs. Clinical medication and substance-use monitoring represents approximately 23.4% and typically carries higher revenue per case because definitive analytical testing and larger drug panels are more common. Legal, judicial, corrections and forensic applications account for roughly 13%, while personal and other commercial testing represents the remaining high-single-digit share. These segments differ materially in testing frequency, specimen selection, laboratory intensity and purchasing behavior.
By specimen type, urine remains the core commercial testing matrix by volume because of its established laboratory infrastructure and widespread use in regulated and employer programs. However, the service mix is becoming more diversified. Oral fluid provides a directly observable collection route, hair and nail testing support longer retrospective detection windows, and blood or specialized alcohol biomarkers serve selected clinical and forensic applications. This diversification favors providers with multi-matrix capability and strong confirmatory testing infrastructure rather than companies dependent on a single standardized testing workflow.
Downstream Market Opportunities
The largest downstream opportunity continues to come from employers and safety-sensitive industries, especially where drug and alcohol testing is embedded in occupational-risk management rather than treated as a one-time recruitment procedure. Transportation, energy, mining, construction and industrial operations create recurring testing requirements, while healthcare and behavioral-health customers increasingly require definitive toxicology for medication and substance-use monitoring. Courts, corrections and social-service agencies support demand for documented and legally defensible testing, and specialist long-window testing creates additional opportunities in family-law and personal applications. The most valuable customer relationships are increasingly those that combine testing with program administration, rapid access to collection sites, digital compliance records and consistent service across multiple operating locations.
Regional Insights
North America is the largest regional market, representing approximately 68%–70% of 2025 revenue under the report’s commercial-services definition. The region benefits from a mature employer-testing ecosystem, substantial clinical toxicology activity, extensive laboratory and collection infrastructure, and formal testing requirements in safety-sensitive transportation sectors. Europe represents approximately 14%–15%, with the United Kingdom standing out for its relatively developed workplace and specialist toxicology service ecosystem. Asia Pacific contributes approximately 11%–13%, although the regional structure is more heterogeneous: Australia and New Zealand have relatively mature occupational testing markets, Japan has established specialist laboratory capabilities, while China and India rely more heavily on forensic toxicology and broader diagnostic laboratory networks.
From an expansion perspective, Asia Pacific offers meaningful white-space opportunity because commercial service models remain less standardized across many countries and outsourcing penetration varies considerably. North America, by contrast, is likely to remain the principal revenue pool but is more mature and competitive. Regulatory structures are a major source of regional differentiation; in the United States, SAMHSA maintains the HHS-certified laboratory framework and the DOT maintains detailed procedures for federally regulated workplace testing, while other regions operate under substantially different labor, privacy and occupational-health regimes.
Competitive Landscape Analysis
The competitive landscape of Alcohol and Drug Abuse Testing Service is characterized by large laboratory and screening platforms at the top of the market and a broad long tail of regional and technically specialized providers. Quest Diagnostics and Labcorp compete through laboratory capacity, collection reach, employer relationships and multi-specimen testing capabilities, while Abbott combines toxicology testing with the eScreen workplace-testing ecosystem. DISA, First Advantage and other screening administrators compete more strongly through customer access, compliance management and integrated workflows, whereas Millennium Health, Aegis Sciences, Omega Laboratories, Psychemedics and other specialist laboratories differentiate through definitive toxicology, alternative specimens or specialized clinical and legal applications. Consolidation is gradually strengthening integrated service platforms: First Advantage completed its acquisition of Sterling Check in October 2024, broadening its screening platform and geographic reach. Outside North America, competition remains more regionally fragmented, with Eurofins and SYNLAB combining broader laboratory networks with toxicology capabilities, Randox and Medigold maintaining specialist positions in the United Kingdom, and TDDA and other providers serving mature occupational-testing demand in Australia and New Zealand. Future competitive advantage is expected to depend increasingly on multi-matrix testing, definitive analytical capability, digital chain-of-custody, geographic collection coverage and the ability to manage compliance-intensive customer programs rather than laboratory capacity alone.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Alcohol and Drug Abuse Testing Service market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Quest Diagnostics
Labcorp
Abbott Laboratories
Millennium Health
Aegis Sciences
First Advantage
DISA Global Solutions
Concentra
Clinical Reference Laboratory
Cordant Health Solutions
Eurofins Scientific
Sonic Healthcare
HireRight
DRUGSCAN
Omega Laboratories
Averhealth
SYNLAB Group
Randox Laboratories
CannAmm
Pacific Toxicology
DriverCheck
USDTL
Medigold Health
PHC Holdings
Dynacare
AlphaBiolabs
SureHire
TDDA
Phamatech
Psychemedics
Safework Health
Joincare Pharmaceutical Group Industry Co., Ltd.
National Drug Screening
WorkforceQA
AusHealth
Health Street
Segment by Type
Pre-placement Testing
Periodic Testing
Reasonable-suspicion Testing
Return-to-Duty and Follow-up Testing
Others
Segment by Specimen Type
Urine Testing
Saliva Testing
Hair Testing
Blood Testing
Others
Segment by Service Component
Specimen Collection Services
Initial Screening Services
Definitive Laboratory Testing
Medical Review Officer Services
Others
Segment by Application
Employers and Safety-sensitive Industries
Healthcare and Substance-use Treatment Providers
Corrections and Social Services
Others
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Alcohol and Drug Abuse Testing Service study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Alcohol and Drug Abuse Testing Service: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Alcohol and Drug Abuse Testing Service Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Pre-placement Testing
1.2.3 Periodic Testing
1.2.4 Reasonable-suspicion Testing
1.2.5 Return-to-Duty and Follow-up Testing
1.2.6 Others
1.3 Market Segmentation by Specimen Type
1.3.1 Global Alcohol and Drug Abuse Testing Service Market Size by Specimen Type, 2021 vs 2025 vs 2032
1.3.2 Urine Testing
1.3.3 Saliva Testing
1.3.4 Hair Testing
1.3.5 Blood Testing
1.3.6 Others
1.4 Market Segmentation by Service Component
1.4.1 Global Alcohol and Drug Abuse Testing Service Market Size by Service Component, 2021 vs 2025 vs 2032
1.4.2 Specimen Collection Services
1.4.3 Initial Screening Services
1.4.4 Definitive Laboratory Testing
1.4.5 Medical Review Officer Services
1.4.6 Others
1.5 Market Segmentation by Application
1.5.1 Global Alcohol and Drug Abuse Testing Service Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Employers and Safety-sensitive Industries
1.5.3 Healthcare and Substance-use Treatment Providers
1.5.4 Corrections and Social Services
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Alcohol and Drug Abuse Testing Service Revenue Estimates and Forecasts (2021-2032)
2.2 Global Alcohol and Drug Abuse Testing Service Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Alcohol and Drug Abuse Testing Service Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Alcohol and Drug Abuse Testing Service Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Pre-placement Testing: Market Share by Key Players
3.3.2 Periodic Testing: Market Share by Key Players
3.3.3 Reasonable-suspicion Testing: Market Share by Key Players
3.3.4 Return-to-Duty and Follow-up Testing: Market Share by Key Players
3.3.5 Others: Market Share by Key Players
3.4 Global Alcohol and Drug Abuse Testing Service Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Alcohol and Drug Abuse Testing Service Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Alcohol and Drug Abuse Testing Service Market by Specimen Type
4.2.1 Global Revenue by Specimen Type (2021-2032)
4.2.2 Global Revenue-Based Market Share by Specimen Type (2021-2032)
4.3 Global Alcohol and Drug Abuse Testing Service Market by Service Component
4.3.1 Global Revenue by Service Component (2021-2032)
4.3.2 Global Revenue-Based Market Share by Service Component (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Alcohol and Drug Abuse Testing Service Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Alcohol and Drug Abuse Testing Service Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Alcohol and Drug Abuse Testing Service Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Alcohol and Drug Abuse Testing Service Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Alcohol and Drug Abuse Testing Service Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Alcohol and Drug Abuse Testing Service Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Alcohol and Drug Abuse Testing Service Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Alcohol and Drug Abuse Testing Service Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Alcohol and Drug Abuse Testing Service Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Alcohol and Drug Abuse Testing Service Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Alcohol and Drug Abuse Testing Service Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Quest Diagnostics
11.1.1 Quest Diagnostics Corporation Information
11.1.2 Quest Diagnostics Business Overview
11.1.3 Quest Diagnostics Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.1.4 Quest Diagnostics Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.1.5 Quest Diagnostics Alcohol and Drug Abuse Testing Service Revenue by Product in 2025
11.1.6 Quest Diagnostics Alcohol and Drug Abuse Testing Service Revenue by Application in 2025
11.1.7 Quest Diagnostics Alcohol and Drug Abuse Testing Service Revenue by Geographic Area in 2025
11.1.8 Quest Diagnostics Alcohol and Drug Abuse Testing Service SWOT Analysis
11.1.9 Quest Diagnostics Recent Developments
11.2 Labcorp
11.2.1 Labcorp Corporation Information
11.2.2 Labcorp Business Overview
11.2.3 Labcorp Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.2.4 Labcorp Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.2.5 Labcorp Alcohol and Drug Abuse Testing Service Revenue by Product in 2025
11.2.6 Labcorp Alcohol and Drug Abuse Testing Service Revenue by Application in 2025
11.2.7 Labcorp Alcohol and Drug Abuse Testing Service Revenue by Geographic Area in 2025
11.2.8 Labcorp Alcohol and Drug Abuse Testing Service SWOT Analysis
11.2.9 Labcorp Recent Developments
11.3 Abbott Laboratories
11.3.1 Abbott Laboratories Corporation Information
11.3.2 Abbott Laboratories Business Overview
11.3.3 Abbott Laboratories Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.3.4 Abbott Laboratories Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.3.5 Abbott Laboratories Alcohol and Drug Abuse Testing Service Revenue by Product in 2025
11.3.6 Abbott Laboratories Alcohol and Drug Abuse Testing Service Revenue by Application in 2025
11.3.7 Abbott Laboratories Alcohol and Drug Abuse Testing Service Revenue by Geographic Area in 2025
11.3.8 Abbott Laboratories Alcohol and Drug Abuse Testing Service SWOT Analysis
11.3.9 Abbott Laboratories Recent Developments
11.4 Millennium Health
11.4.1 Millennium Health Corporation Information
11.4.2 Millennium Health Business Overview
11.4.3 Millennium Health Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.4.4 Millennium Health Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.4.5 Millennium Health Alcohol and Drug Abuse Testing Service Revenue by Product in 2025
11.4.6 Millennium Health Alcohol and Drug Abuse Testing Service Revenue by Application in 2025
11.4.7 Millennium Health Alcohol and Drug Abuse Testing Service Revenue by Geographic Area in 2025
11.4.8 Millennium Health Alcohol and Drug Abuse Testing Service SWOT Analysis
11.4.9 Millennium Health Recent Developments
11.5 Aegis Sciences
11.5.1 Aegis Sciences Corporation Information
11.5.2 Aegis Sciences Business Overview
11.5.3 Aegis Sciences Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.5.4 Aegis Sciences Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.5.5 Aegis Sciences Alcohol and Drug Abuse Testing Service Revenue by Product in 2025
11.5.6 Aegis Sciences Alcohol and Drug Abuse Testing Service Revenue by Application in 2025
11.5.7 Aegis Sciences Alcohol and Drug Abuse Testing Service Revenue by Geographic Area in 2025
11.5.8 Aegis Sciences Alcohol and Drug Abuse Testing Service SWOT Analysis
11.5.9 Aegis Sciences Recent Developments
11.6 First Advantage
11.6.1 First Advantage Corporation Information
11.6.2 First Advantage Business Overview
11.6.3 First Advantage Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.6.4 First Advantage Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.6.5 First Advantage Recent Developments
11.7 DISA Global Solutions
11.7.1 DISA Global Solutions Corporation Information
11.7.2 DISA Global Solutions Business Overview
11.7.3 DISA Global Solutions Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.7.4 DISA Global Solutions Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.7.5 DISA Global Solutions Recent Developments
11.8 Concentra
11.8.1 Concentra Corporation Information
11.8.2 Concentra Business Overview
11.8.3 Concentra Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.8.4 Concentra Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.8.5 Concentra Recent Developments
11.9 Clinical Reference Laboratory
11.9.1 Clinical Reference Laboratory Corporation Information
11.9.2 Clinical Reference Laboratory Business Overview
11.9.3 Clinical Reference Laboratory Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.9.4 Clinical Reference Laboratory Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.9.5 Clinical Reference Laboratory Recent Developments
11.10 Cordant Health Solutions
11.10.1 Cordant Health Solutions Corporation Information
11.10.2 Cordant Health Solutions Business Overview
11.10.3 Cordant Health Solutions Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.10.4 Cordant Health Solutions Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Eurofins Scientific
11.11.1 Eurofins Scientific Corporation Information
11.11.2 Eurofins Scientific Business Overview
11.11.3 Eurofins Scientific Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.11.4 Eurofins Scientific Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.11.5 Eurofins Scientific Recent Developments
11.12 Sonic Healthcare
11.12.1 Sonic Healthcare Corporation Information
11.12.2 Sonic Healthcare Business Overview
11.12.3 Sonic Healthcare Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.12.4 Sonic Healthcare Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.12.5 Sonic Healthcare Recent Developments
11.13 HireRight
11.13.1 HireRight Corporation Information
11.13.2 HireRight Business Overview
11.13.3 HireRight Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.13.4 HireRight Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.13.5 HireRight Recent Developments
11.14 DRUGSCAN
11.14.1 DRUGSCAN Corporation Information
11.14.2 DRUGSCAN Business Overview
11.14.3 DRUGSCAN Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.14.4 DRUGSCAN Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.14.5 DRUGSCAN Recent Developments
11.15 Omega Laboratories
11.15.1 Omega Laboratories Corporation Information
11.15.2 Omega Laboratories Business Overview
11.15.3 Omega Laboratories Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.15.4 Omega Laboratories Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.15.5 Omega Laboratories Recent Developments
11.16 Averhealth
11.16.1 Averhealth Corporation Information
11.16.2 Averhealth Business Overview
11.16.3 Averhealth Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.16.4 Averhealth Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.16.5 Averhealth Recent Developments
11.17 SYNLAB Group
11.17.1 SYNLAB Group Corporation Information
11.17.2 SYNLAB Group Business Overview
11.17.3 SYNLAB Group Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.17.4 SYNLAB Group Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.17.5 SYNLAB Group Recent Developments
11.18 Randox Laboratories
11.18.1 Randox Laboratories Corporation Information
11.18.2 Randox Laboratories Business Overview
11.18.3 Randox Laboratories Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.18.4 Randox Laboratories Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.18.5 Randox Laboratories Recent Developments
11.19 CannAmm
11.19.1 CannAmm Corporation Information
11.19.2 CannAmm Business Overview
11.19.3 CannAmm Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.19.4 CannAmm Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.19.5 CannAmm Recent Developments
11.20 Pacific Toxicology
11.20.1 Pacific Toxicology Corporation Information
11.20.2 Pacific Toxicology Business Overview
11.20.3 Pacific Toxicology Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.20.4 Pacific Toxicology Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.20.5 Pacific Toxicology Recent Developments
11.21 DriverCheck
11.21.1 DriverCheck Corporation Information
11.21.2 DriverCheck Business Overview
11.21.3 DriverCheck Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.21.4 DriverCheck Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.21.5 DriverCheck Recent Developments
11.22 USDTL
11.22.1 USDTL Corporation Information
11.22.2 USDTL Business Overview
11.22.3 USDTL Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.22.4 USDTL Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.22.5 USDTL Recent Developments
11.23 Medigold Health
11.23.1 Medigold Health Corporation Information
11.23.2 Medigold Health Business Overview
11.23.3 Medigold Health Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.23.4 Medigold Health Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.23.5 Medigold Health Recent Developments
11.24 PHC Holdings
11.24.1 PHC Holdings Corporation Information
11.24.2 PHC Holdings Business Overview
11.24.3 PHC Holdings Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.24.4 PHC Holdings Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.24.5 PHC Holdings Recent Developments
11.25 Dynacare
11.25.1 Dynacare Corporation Information
11.25.2 Dynacare Business Overview
11.25.3 Dynacare Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.25.4 Dynacare Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.25.5 Dynacare Recent Developments
11.26 AlphaBiolabs
11.26.1 AlphaBiolabs Corporation Information
11.26.2 AlphaBiolabs Business Overview
11.26.3 AlphaBiolabs Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.26.4 AlphaBiolabs Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.26.5 AlphaBiolabs Recent Developments
11.27 SureHire
11.27.1 SureHire Corporation Information
11.27.2 SureHire Business Overview
11.27.3 SureHire Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.27.4 SureHire Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.27.5 SureHire Recent Developments
11.28 TDDA
11.28.1 TDDA Corporation Information
11.28.2 TDDA Business Overview
11.28.3 TDDA Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.28.4 TDDA Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.28.5 TDDA Recent Developments
11.29 Phamatech
11.29.1 Phamatech Corporation Information
11.29.2 Phamatech Business Overview
11.29.3 Phamatech Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.29.4 Phamatech Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.29.5 Phamatech Recent Developments
11.30 Psychemedics
11.30.1 Psychemedics Corporation Information
11.30.2 Psychemedics Business Overview
11.30.3 Psychemedics Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.30.4 Psychemedics Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.30.5 Psychemedics Recent Developments
11.31 Safework Health
11.31.1 Safework Health Corporation Information
11.31.2 Safework Health Business Overview
11.31.3 Safework Health Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.31.4 Safework Health Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.31.5 Safework Health Recent Developments
11.32 Joincare Pharmaceutical Group Industry Co., Ltd.
11.32.1 Joincare Pharmaceutical Group Industry Co., Ltd. Corporation Information
11.32.2 Joincare Pharmaceutical Group Industry Co., Ltd. Business Overview
11.32.3 Joincare Pharmaceutical Group Industry Co., Ltd. Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.32.4 Joincare Pharmaceutical Group Industry Co., Ltd. Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.32.5 Joincare Pharmaceutical Group Industry Co., Ltd. Recent Developments
11.33 National Drug Screening
11.33.1 National Drug Screening Corporation Information
11.33.2 National Drug Screening Business Overview
11.33.3 National Drug Screening Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.33.4 National Drug Screening Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.33.5 National Drug Screening Recent Developments
11.34 WorkforceQA
11.34.1 WorkforceQA Corporation Information
11.34.2 WorkforceQA Business Overview
11.34.3 WorkforceQA Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.34.4 WorkforceQA Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.34.5 WorkforceQA Recent Developments
11.35 AusHealth
11.35.1 AusHealth Corporation Information
11.35.2 AusHealth Business Overview
11.35.3 AusHealth Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.35.4 AusHealth Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.35.5 AusHealth Recent Developments
11.36 Health Street
11.36.1 Health Street Corporation Information
11.36.2 Health Street Business Overview
11.36.3 Health Street Alcohol and Drug Abuse Testing Service Product Features and Attributes
11.36.4 Health Street Alcohol and Drug Abuse Testing Service Revenue and Gross Margin (2021-2026)
11.36.5 Health Street Recent Developments

12 Alcohol and Drug Abuse Testing Service Value Chain and Ecosystem Analysis
12.1 Alcohol and Drug Abuse Testing Service Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Alcohol and Drug Abuse Testing Service Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Alcohol and Drug Abuse Testing Service Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Alcohol and Drug Abuse Testing Service Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Alcohol and Drug Abuse Testing Service Market Size Growth Rate by Specimen Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Alcohol and Drug Abuse Testing Service Market Size Growth Rate by Service Component, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Alcohol and Drug Abuse Testing Service Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Alcohol and Drug Abuse Testing Service Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Alcohol and Drug Abuse Testing Service Revenue by Region (US$ Million), 2021-2026
Table 7. Global Alcohol and Drug Abuse Testing Service Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Alcohol and Drug Abuse Testing Service Revenue by Players (US$ Million), 2021-2026
Table 10. Global Alcohol and Drug Abuse Testing Service Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Alcohol and Drug Abuse Testing Service Revenue, 2025
Table 13. Global Alcohol and Drug Abuse Testing Service Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Alcohol and Drug Abuse Testing Service Companies Headquarters
Table 15. Global Alcohol and Drug Abuse Testing Service Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Alcohol and Drug Abuse Testing Service Revenue by Type (US$ Million), 2021-2026
Table 19. Global Alcohol and Drug Abuse Testing Service Revenue by Type (US$ Million), 2027-2032
Table 20. Global Alcohol and Drug Abuse Testing Service Revenue by Specimen Type (US$ Million), 2021-2026
Table 21. Global Alcohol and Drug Abuse Testing Service Revenue by Specimen Type (US$ Million), 2027-2032
Table 22. Global Alcohol and Drug Abuse Testing Service Revenue by Service Component (US$ Million), 2021-2026
Table 23. Global Alcohol and Drug Abuse Testing Service Revenue by Service Component (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Alcohol and Drug Abuse Testing Service Revenue by Application (US$ Million), 2021-2026
Table 26. Global Alcohol and Drug Abuse Testing Service Revenue by Application (US$ Million), 2027-2032
Table 27. Alcohol and Drug Abuse Testing Service High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Alcohol and Drug Abuse Testing Service Growth Accelerators and Market Barriers
Table 31. North America Alcohol and Drug Abuse Testing Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Alcohol and Drug Abuse Testing Service Growth Accelerators and Market Barriers
Table 33. Europe Alcohol and Drug Abuse Testing Service Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Alcohol and Drug Abuse Testing Service Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Alcohol and Drug Abuse Testing Service Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Alcohol and Drug Abuse Testing Service Investment Opportunities and Key Challenges
Table 37. Central and South America Alcohol and Drug Abuse Testing Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Alcohol and Drug Abuse Testing Service Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Alcohol and Drug Abuse Testing Service Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Quest Diagnostics Corporation Information
Table 41. Quest Diagnostics Description and Major Businesses
Table 42. Quest Diagnostics Product Features and Attributes
Table 43. Quest Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Quest Diagnostics Revenue Proportion by Product in 2025
Table 45. Quest Diagnostics Revenue Proportion by Application in 2025
Table 46. Quest Diagnostics Revenue Proportion by Geographic Area in 2025
Table 47. Quest Diagnostics Alcohol and Drug Abuse Testing Service SWOT Analysis
Table 48. Quest Diagnostics Recent Developments
Table 49. Labcorp Corporation Information
Table 50. Labcorp Description and Major Businesses
Table 51. Labcorp Product Features and Attributes
Table 52. Labcorp Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Labcorp Revenue Proportion by Product in 2025
Table 54. Labcorp Revenue Proportion by Application in 2025
Table 55. Labcorp Revenue Proportion by Geographic Area in 2025
Table 56. Labcorp Alcohol and Drug Abuse Testing Service SWOT Analysis
Table 57. Labcorp Recent Developments
Table 58. Abbott Laboratories Corporation Information
Table 59. Abbott Laboratories Description and Major Businesses
Table 60. Abbott Laboratories Product Features and Attributes
Table 61. Abbott Laboratories Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Abbott Laboratories Revenue Proportion by Product in 2025
Table 63. Abbott Laboratories Revenue Proportion by Application in 2025
Table 64. Abbott Laboratories Revenue Proportion by Geographic Area in 2025
Table 65. Abbott Laboratories Alcohol and Drug Abuse Testing Service SWOT Analysis
Table 66. Abbott Laboratories Recent Developments
Table 67. Millennium Health Corporation Information
Table 68. Millennium Health Description and Major Businesses
Table 69. Millennium Health Product Features and Attributes
Table 70. Millennium Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Millennium Health Revenue Proportion by Product in 2025
Table 72. Millennium Health Revenue Proportion by Application in 2025
Table 73. Millennium Health Revenue Proportion by Geographic Area in 2025
Table 74. Millennium Health Alcohol and Drug Abuse Testing Service SWOT Analysis
Table 75. Millennium Health Recent Developments
Table 76. Aegis Sciences Corporation Information
Table 77. Aegis Sciences Description and Major Businesses
Table 78. Aegis Sciences Product Features and Attributes
Table 79. Aegis Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Aegis Sciences Revenue Proportion by Product in 2025
Table 81. Aegis Sciences Revenue Proportion by Application in 2025
Table 82. Aegis Sciences Revenue Proportion by Geographic Area in 2025
Table 83. Aegis Sciences Alcohol and Drug Abuse Testing Service SWOT Analysis
Table 84. Aegis Sciences Recent Developments
Table 85. First Advantage Corporation Information
Table 86. First Advantage Description and Major Businesses
Table 87. First Advantage Product Features and Attributes
Table 88. First Advantage Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. First Advantage Recent Developments
Table 90. DISA Global Solutions Corporation Information
Table 91. DISA Global Solutions Description and Major Businesses
Table 92. DISA Global Solutions Product Features and Attributes
Table 93. DISA Global Solutions Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. DISA Global Solutions Recent Developments
Table 95. Concentra Corporation Information
Table 96. Concentra Description and Major Businesses
Table 97. Concentra Product Features and Attributes
Table 98. Concentra Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Concentra Recent Developments
Table 100. Clinical Reference Laboratory Corporation Information
Table 101. Clinical Reference Laboratory Description and Major Businesses
Table 102. Clinical Reference Laboratory Product Features and Attributes
Table 103. Clinical Reference Laboratory Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Clinical Reference Laboratory Recent Developments
Table 105. Cordant Health Solutions Corporation Information
Table 106. Cordant Health Solutions Description and Major Businesses
Table 107. Cordant Health Solutions Product Features and Attributes
Table 108. Cordant Health Solutions Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Cordant Health Solutions Recent Developments
Table 110. Eurofins Scientific Corporation Information
Table 111. Eurofins Scientific Description and Major Businesses
Table 112. Eurofins Scientific Product Features and Attributes
Table 113. Eurofins Scientific Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Eurofins Scientific Recent Developments
Table 115. Sonic Healthcare Corporation Information
Table 116. Sonic Healthcare Description and Major Businesses
Table 117. Sonic Healthcare Product Features and Attributes
Table 118. Sonic Healthcare Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Sonic Healthcare Recent Developments
Table 120. HireRight Corporation Information
Table 121. HireRight Description and Major Businesses
Table 122. HireRight Product Features and Attributes
Table 123. HireRight Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. HireRight Recent Developments
Table 125. DRUGSCAN Corporation Information
Table 126. DRUGSCAN Description and Major Businesses
Table 127. DRUGSCAN Product Features and Attributes
Table 128. DRUGSCAN Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. DRUGSCAN Recent Developments
Table 130. Omega Laboratories Corporation Information
Table 131. Omega Laboratories Description and Major Businesses
Table 132. Omega Laboratories Product Features and Attributes
Table 133. Omega Laboratories Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Omega Laboratories Recent Developments
Table 135. Averhealth Corporation Information
Table 136. Averhealth Description and Major Businesses
Table 137. Averhealth Product Features and Attributes
Table 138. Averhealth Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Averhealth Recent Developments
Table 140. SYNLAB Group Corporation Information
Table 141. SYNLAB Group Description and Major Businesses
Table 142. SYNLAB Group Product Features and Attributes
Table 143. SYNLAB Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. SYNLAB Group Recent Developments
Table 145. Randox Laboratories Corporation Information
Table 146. Randox Laboratories Description and Major Businesses
Table 147. Randox Laboratories Product Features and Attributes
Table 148. Randox Laboratories Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Randox Laboratories Recent Developments
Table 150. CannAmm Corporation Information
Table 151. CannAmm Description and Major Businesses
Table 152. CannAmm Product Features and Attributes
Table 153. CannAmm Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. CannAmm Recent Developments
Table 155. Pacific Toxicology Corporation Information
Table 156. Pacific Toxicology Description and Major Businesses
Table 157. Pacific Toxicology Product Features and Attributes
Table 158. Pacific Toxicology Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Pacific Toxicology Recent Developments
Table 160. DriverCheck Corporation Information
Table 161. DriverCheck Description and Major Businesses
Table 162. DriverCheck Product Features and Attributes
Table 163. DriverCheck Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. DriverCheck Recent Developments
Table 165. USDTL Corporation Information
Table 166. USDTL Description and Major Businesses
Table 167. USDTL Product Features and Attributes
Table 168. USDTL Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. USDTL Recent Developments
Table 170. Medigold Health Corporation Information
Table 171. Medigold Health Description and Major Businesses
Table 172. Medigold Health Product Features and Attributes
Table 173. Medigold Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Medigold Health Recent Developments
Table 175. PHC Holdings Corporation Information
Table 176. PHC Holdings Description and Major Businesses
Table 177. PHC Holdings Product Features and Attributes
Table 178. PHC Holdings Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. PHC Holdings Recent Developments
Table 180. Dynacare Corporation Information
Table 181. Dynacare Description and Major Businesses
Table 182. Dynacare Product Features and Attributes
Table 183. Dynacare Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Dynacare Recent Developments
Table 185. AlphaBiolabs Corporation Information
Table 186. AlphaBiolabs Description and Major Businesses
Table 187. AlphaBiolabs Product Features and Attributes
Table 188. AlphaBiolabs Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. AlphaBiolabs Recent Developments
Table 190. SureHire Corporation Information
Table 191. SureHire Description and Major Businesses
Table 192. SureHire Product Features and Attributes
Table 193. SureHire Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. SureHire Recent Developments
Table 195. TDDA Corporation Information
Table 196. TDDA Description and Major Businesses
Table 197. TDDA Product Features and Attributes
Table 198. TDDA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. TDDA Recent Developments
Table 200. Phamatech Corporation Information
Table 201. Phamatech Description and Major Businesses
Table 202. Phamatech Product Features and Attributes
Table 203. Phamatech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. Phamatech Recent Developments
Table 205. Psychemedics Corporation Information
Table 206. Psychemedics Description and Major Businesses
Table 207. Psychemedics Product Features and Attributes
Table 208. Psychemedics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. Psychemedics Recent Developments
Table 210. Safework Health Corporation Information
Table 211. Safework Health Description and Major Businesses
Table 212. Safework Health Product Features and Attributes
Table 213. Safework Health Revenue (US$ Million) and Gross Margin (2021-2026)
Table 214. Safework Health Recent Developments
Table 215. Joincare Pharmaceutical Group Industry Co., Ltd. Corporation Information
Table 216. Joincare Pharmaceutical Group Industry Co., Ltd. Description and Major Businesses
Table 217. Joincare Pharmaceutical Group Industry Co., Ltd. Product Features and Attributes
Table 218. Joincare Pharmaceutical Group Industry Co., Ltd. Revenue (US$ Million) and Gross Margin (2021-2026)
Table 219. Joincare Pharmaceutical Group Industry Co., Ltd. Recent Developments
Table 220. National Drug Screening Corporation Information
Table 221. National Drug Screening Description and Major Businesses
Table 222. National Drug Screening Product Features and Attributes
Table 223. National Drug Screening Revenue (US$ Million) and Gross Margin (2021-2026)
Table 224. National Drug Screening Recent Developments
Table 225. WorkforceQA Corporation Information
Table 226. WorkforceQA Description and Major Businesses
Table 227. WorkforceQA Product Features and Attributes
Table 228. WorkforceQA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 229. WorkforceQA Recent Developments
Table 230. AusHealth Corporation Information
Table 231. AusHealth Description and Major Businesses
Table 232. AusHealth Product Features and Attributes
Table 233. AusHealth Revenue (US$ Million) and Gross Margin (2021-2026)
Table 234. AusHealth Recent Developments
Table 235. Health Street Corporation Information
Table 236. Health Street Description and Major Businesses
Table 237. Health Street Product Features and Attributes
Table 238. Health Street Revenue (US$ Million) and Gross Margin (2021-2026)
Table 239. Health Street Recent Developments
Table 240. Technologies, Platforms and Infrastructure
Table 241. Distributors List
Table 242. Market Trends and Market Evolution
Table 243. Market Drivers and Opportunities
Table 244. Market Challenges, Risks, and Restraints
Table 245. Research Programs/Design for This Report
Table 246. Key Data Information from Secondary Sources
Table 247. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Alcohol and Drug Abuse Testing Service Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Pre-placement Testing Product Picture
Figure 3. Periodic Testing Product Picture
Figure 4. Reasonable-suspicion Testing Product Picture
Figure 5. Return-to-Duty and Follow-up Testing Product Picture
Figure 6. Others Product Picture
Figure 7. Global Alcohol and Drug Abuse Testing Service Market Size Growth Rate by Specimen Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. Urine Testing Product Picture
Figure 9. Saliva Testing Product Picture
Figure 10. Hair Testing Product Picture
Figure 11. Blood Testing Product Picture
Figure 12. Others Product Picture
Figure 13. Global Alcohol and Drug Abuse Testing Service Market Size Growth Rate by Service Component, 2021 vs 2025 vs 2032 (US$ Million)
Figure 14. Specimen Collection Services Product Picture
Figure 15. Initial Screening Services Product Picture
Figure 16. Definitive Laboratory Testing Product Picture
Figure 17. Medical Review Officer Services Product Picture
Figure 18. Others Product Picture
Figure 19. Global Alcohol and Drug Abuse Testing Service Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 20. Employers and Safety-sensitive Industries
Figure 21. Healthcare and Substance-use Treatment Providers
Figure 22. Corrections and Social Services
Figure 23. Others
Figure 24. Alcohol and Drug Abuse Testing Service Report Years Considered
Figure 25. Global Alcohol and Drug Abuse Testing Service Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 26. Global Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 27. Global Alcohol and Drug Abuse Testing Service Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 28. Global Alcohol and Drug Abuse Testing Service Revenue-Based Market Share by Region (2021-2032)
Figure 29. Global Alcohol and Drug Abuse Testing Service Revenue-Based Market Share Ranking (2025)
Figure 30. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 31. Pre-placement Testing Revenue-Based Market Share by Player in 2025
Figure 32. Periodic Testing Revenue-Based Market Share by Player in 2025
Figure 33. Reasonable-suspicion Testing Revenue-Based Market Share by Player in 2025
Figure 34. Return-to-Duty and Follow-up Testing Revenue-Based Market Share by Player in 2025
Figure 35. Others Revenue-Based Market Share by Player in 2025
Figure 36. Global Alcohol and Drug Abuse Testing Service Revenue-Based Market Share by Type (2021-2032)
Figure 37. Global Alcohol and Drug Abuse Testing Service Revenue-Based Market Share by Specimen Type (2021-2032)
Figure 38. Global Alcohol and Drug Abuse Testing Service Revenue-Based Market Share by Service Component (2021-2032)
Figure 39. Global Alcohol and Drug Abuse Testing Service Revenue-Based Market Share by Application (2021-2032)
Figure 40. North America Alcohol and Drug Abuse Testing Service Revenue YoY (US$ Million), 2021-2032
Figure 41. North America Top 5 Players Alcohol and Drug Abuse Testing Service Revenue (US$ Million) in 2025
Figure 42. North America Alcohol and Drug Abuse Testing Service Revenue (US$ Million) by Application (2021-2032)
Figure 43. US Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 44. Canada Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 45. Mexico Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 46. Europe Alcohol and Drug Abuse Testing Service Revenue YoY (US$ Million), 2021-2032
Figure 47. Europe Top 5 Players Alcohol and Drug Abuse Testing Service Revenue (US$ Million) in 2025
Figure 48. Europe Alcohol and Drug Abuse Testing Service Revenue (US$ Million) by Application (2021-2032)
Figure 49. Germany Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 50. France Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 51. U.K. Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 52. Italy Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 53. Russia Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 54. Asia-Pacific Alcohol and Drug Abuse Testing Service Revenue YoY (US$ Million), 2021-2032
Figure 55. Asia-Pacific Top 8 Players Alcohol and Drug Abuse Testing Service Revenue (US$ Million) in 2025
Figure 56. Asia-Pacific Alcohol and Drug Abuse Testing Service Revenue (US$ Million) by Application (2021-2032)
Figure 57. Indonesia Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 58. Japan Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 59. South Korea Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 60. Australia Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 61. India Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 62. Indonesia Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 63. Vietnam Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 64. Malaysia Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 65. Philippines Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 66. Singapore Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 67. Central and South America Alcohol and Drug Abuse Testing Service Revenue YoY (US$ Million), 2021-2032
Figure 68. Central and South America Top 5 Players Alcohol and Drug Abuse Testing Service Revenue (US$ Million) in 2025
Figure 69. Central and South America Alcohol and Drug Abuse Testing Service Revenue (US$ Million) by Application (2021-2032)
Figure 70. Brazil Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 71. Argentina Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 72. Middle East and Africa Alcohol and Drug Abuse Testing Service Revenue YoY (US$ Million), 2021-2032
Figure 73. Middle East and Africa Top 5 Players Alcohol and Drug Abuse Testing Service Revenue (US$ Million) in 2025
Figure 74. Middle East and Africa Alcohol and Drug Abuse Testing Service Revenue (US$ Million) by Application (2021-2032)
Figure 75. GCC Countries Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 76. Israel Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 77. Egypt Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 78. South Africa Alcohol and Drug Abuse Testing Service Revenue (US$ Million), 2021-2032
Figure 79. Alcohol and Drug Abuse Testing Service Value Chain Mapping
Figure 80. Channels of Distribution (Direct Vs Distribution)
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed